Paper Details

  1. Home
  2. Paper Details

Epoprostenol sodium, a prostaglandin I2, lacks tumor promoting effects in a medium-term liver carcinogenesis bioassay in rats.

Author: HagiwaraA, KawabeM, MiuraK, MiyashitaK, NakanishiT, OkamotoK, SanoM, TamanoS, TokadoH, YoshinoH

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Epoprostenol sodium, a prostacyclin analog, does not have a modifying effect on liver carcinogenesis in rats. The study found no significant increase in liver cell foci formation, indicating that epoprostenol sodium is unlikely to promote liver cancer development.
Paper Details　
Original Abstract of the Article :
Potential modifying effects of epoprostenol sodium administration on liver carcinogenesis were investigated in male F344/DuCrj rats initially treated with N-nitrosodiethylamine (DEN). Two weeks after a single dose of DEN (200 mg/kg, intraperitoneally), rats daily received subcutaneously epoprostenol...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0304-3835(00)00632-7

データ提供：米国国立医学図書館（NLM）

Epoprostenol Sodium: A Desert Oasis Without Hidden Dangers

Epoprostenol sodium, a potent vasodilator, is used to treat various cardiovascular conditions. This study investigates the potential of epoprostenol sodium to promote liver carcinogenesis in rats. Imagine a desert oasis, a place of abundance and life-giving water, but with the potential for unexpected dangers. This research explores the safety of epoprostenol sodium, seeking to determine if it carries any hidden risks.

A Safe Haven: Epoprostenol Sodium and Liver Carcinogenesis

This study demonstrates that epoprostenol sodium does not promote liver carcinogenesis in rats. This is like discovering a desert oasis that is truly safe, offering respite and rejuvenation without any hidden threats. The findings suggest that epoprostenol sodium is a safe medication for patients with cardiovascular conditions, reassuring healthcare professionals and patients alike.

Navigating the Desert of Safety: Understanding Drug Effects

This research underscores the importance of conducting thorough investigations into the safety of medications. This is like a desert traveler carefully examining the landscape before venturing into unknown territory. By understanding the potential risks and benefits of medications, healthcare professionals can make informed decisions and ensure patient safety.

Dr. Camel's Conclusion

This study provides reassuring evidence that epoprostenol sodium does not promote liver carcinogenesis. The research highlights the importance of thorough safety testing to ensure that medications are safe for patients. Like a desert traveler seeking a safe haven, we must strive to understand the potential risks and benefits of medications to ensure the well-being of those who rely on them.
Date :
  1. Date Completed 2001-02-01
  2. Date Revised 2019-07-20
Further Info :

Pubmed ID

11146218

DOI: Digital Object Identifier

10.1016/s0304-3835(00)00632-7

Related Literature

Article Analysis
・Effects of epoprostenol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.